123 related articles for article (PubMed ID: 33044090)
1. Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer.
Chabot I; Zhao Q; Su Y
Curr Med Res Opin; 2020 Dec; 36(12):2025-2036. PubMed ID: 33044090
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes.
Chen L; Yan X; Luo T; Tian T; He P; Zhong X
Cancer Med; 2024 May; 13(10):e7295. PubMed ID: 38785215
[TBL] [Abstract][Full Text] [Related]
3. Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial.
Krasniqi E; Pizzuti L; Valerio MR; Capomolla E; Botti C; Sanguineti G; Marchetti P; Anselmi E; Tomao S; Giordano A; Ficorella C; Cannita K; Livi L; Meattini I; Mauri M; Greco F; Veltri EM; Michelotti A; Moscetti L; Giotta F; Lorusso V; Paris I; Tomao F; Santini D; Tonini G; Villa A; Gebbia V; Gamucci T; Ciliberto G; Sperduti I; Mazzotta M; Barba M; Vici P
Int J Med Sci; 2021; 18(10):2245-2250. PubMed ID: 33859534
[No Abstract] [Full Text] [Related]
4. Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial.
Tolaney SM; Barroso-Sousa R; Keenan T; Li T; Trippa L; Vaz-Luis I; Wulf G; Spring L; Sinclair NF; Andrews C; Pittenger J; Richardson ET; Dillon D; Lin NU; Overmoyer B; Partridge AH; Van Allen E; Mittendorf EA; Winer EP; Krop IE
JAMA Oncol; 2020 Oct; 6(10):1598-1605. PubMed ID: 32880602
[TBL] [Abstract][Full Text] [Related]
5. Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer.
Goyal RK; Zhang J; Davis KL; Sluga-O'Callaghan M; Kaufman PA
Breast Cancer Res Treat; 2024 May; 205(1):201-210. PubMed ID: 38310616
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting.
Inoue K; Takahashi M; Mukai H; Yamanaka T; Egawa C; Sakata Y; Ikezawa H; Matsuoka T; Tsurutani J
Invest New Drugs; 2020 Oct; 38(5):1540-1549. PubMed ID: 31950374
[TBL] [Abstract][Full Text] [Related]
7. Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-Negative Metastatic Breast Cancer and Recurrent Ovarian Cancer.
Landry CA; Blanter J; Ru M; Fasano J; Klein P; Shao T; Bhardwaj A; Tiersten A
Oncology; 2024; 102(1):9-16. PubMed ID: 37598677
[TBL] [Abstract][Full Text] [Related]
8. Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?
Catania G; Malaguti P; Gasparro S; Cognetti F; Vidiri A; Fabi A
Oncology; 2018; 94 Suppl 1(Suppl 1):29-33. PubMed ID: 30041177
[TBL] [Abstract][Full Text] [Related]
9. Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study.
Dell'Ova M; De Maio E; Guiu S; Roca L; Dalenc F; Durigova A; Pinguet F; Bekhtari K; Jacot W; Pouderoux S
BMC Cancer; 2015 Oct; 15():659. PubMed ID: 26449988
[TBL] [Abstract][Full Text] [Related]
10. Eribulin in metastatic breast cancer: Real world data.
Fernández-Laguna CL; Maray I; Macia-Rivas L; Álvarez-Asteinza C; Fernández-Lastras S; Velasco Durántez V; Carbajales Álvarez M; Lozano-Blázquez A
Breast Dis; 2023; 42(1):349-360. PubMed ID: 38073367
[TBL] [Abstract][Full Text] [Related]
11. Early Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Breast Cancer Treated with Eribulin After Prior Immuno-Oncology or Antibody-Drug Conjugate Therapy.
Goyal RK; Zhang J; Davis KL; Sluga-O'Callaghan M; Kaufman PA
Breast Cancer (Dove Med Press); 2023; 15():855-865. PubMed ID: 38020049
[TBL] [Abstract][Full Text] [Related]
12. A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer.
Gumusay O; Huppert LA; Magbanua MJM; Wabl CA; Assefa M; Chien AJ; Melisko ME; Majure MC; Moasser M; Park J; Rugo HS
Breast Cancer Res Treat; 2024 Jan; 203(2):197-204. PubMed ID: 37815684
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of offering multiple chemotherapy lines to a luminal-like metastatic breast cancer: A case report with eribulin.
Valsecchi AA; Paparo J; Pirro V; Manfredi M; Di Maio M; Dionisio R
Tumori; 2023 Dec; 109(6):NP1-NP5. PubMed ID: 36482741
[TBL] [Abstract][Full Text] [Related]
14. Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial).
Orditura M; Gravina A; Riccardi F; Diana A; Mocerino C; Leopaldi L; Fabozzi A; Giordano G; Nettuno R; Incoronato P; Barzelloni ML; Caputo R; Pisano A; Grimaldi G; Genua G; Montesarchio V; Barbato E; Iodice G; Lieto E; Procaccini E; Mabilia R; Febbraro A; Laurentiis M; Ciardiello F
ESMO Open; 2017; 2(2):e000176. PubMed ID: 28761747
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study.
Di Cosimo S; La Verde N; Moretti A; Cazzaniga ME; Generali D; Bianchi GV; Mariani L; Torri V; Crippa F; Paolini B; Scaperrotta G; De Santis MC; Di Nicola M; Apolone G; Gulino A; Tripodo C; Colombo MP; Folli S; de Braud F
PLoS One; 2019; 14(8):e0220644. PubMed ID: 31390375
[TBL] [Abstract][Full Text] [Related]
16. Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study.
Jiang M; Shao B; Wan D; Liu J; He M; Chai Y; Sang D; Wang J; Ma F; Fan Y; Yuan P; Xu B; Li Q
Ther Adv Med Oncol; 2023; 15():17588359231204856. PubMed ID: 37841751
[TBL] [Abstract][Full Text] [Related]
17. Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) in Locally Advanced or Metastatic Breast Cancer: Prospective Cohort Study.
Lück HJ; Schmidt M; Hesse T; Hoffmann O; Heinrich BJ; Park-Simon TW; Grischke EM; Weide R; Müller-Huesmann H; Lüdtke-Heckenkamp K; Fischer D; Zemlin C; Kögel M; Wu J; Schmitz H; Engelbrecht C; Jackisch C
Oncologist; 2023 Dec; 28(12):e1152-e1159. PubMed ID: 37555463
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study.
Huang W; Wang C; Wang L; Shen Y; Chen Q; Huang Z; Liu J; Lin X; Wu F; Chen X; Li N; Hong Y; Chen M; Li J; Huang C
Front Cell Dev Biol; 2024; 12():1313610. PubMed ID: 38481526
[No Abstract] [Full Text] [Related]
19. Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03).
Kobayashi K; Masuda N; Mizuno T; Miura K; Tokuda Y; Yoshinami T; Kawaguchi H; Ohtani S; Saeki T; Toi M; Takeuchi M; Ito Y
Breast Cancer Res Treat; 2023 Oct; 201(3):409-415. PubMed ID: 37480384
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological induction of chromatin remodeling drives chemosensitization in triple-negative breast cancer.
Bagheri M; Mohamed GA; Mohamed Saleem MA; Ognjenovic NB; Lu H; Kolling FW; Wilkins OM; Das S; LaCroix IS; Nagaraj SH; Muller KE; Gerber SA; Miller TW; Pattabiraman DR
Cell Rep Med; 2024 Apr; 5(4):101504. PubMed ID: 38593809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
